Why more mothers are turning to psilocybin when traditional treatments fall short
For some new mothers, the days and weeks after giving birth are not filled with the expected joy. Instead, they are consumed by emotional numbness, anxiety, and a feeling of overwhelming disconnection. Despite their best efforts, many find it difficult to bond with their babies, enjoy the moment, or even feel like themselves.
Often these women feel as though they are not being heard, and that traditional solutions like antidepressants numb them rather than getting to the route of the issue. However, a growing number of mothers are exploring a surprising alternative: psilocybin, the active compound in psychedelic mushrooms.
What once belonged to the fringes of mental health experimentation is now being quietly adopted by a growing number of mothers searching for relief from postpartum depression (PPD) — a condition that affects approximately one in seven women after childbirth.
An Untapped Opportunity in Psychedelic Research
Despite a surge in scientific studies showing psilocybin’s potential for treating depression, PTSD, and addiction, postpartum depression has remained largely neglected. That’s because new mothers pose unique challenges for researchers: fluctuating hormones can affect trial outcomes, and concerns over breastfeeding and infant safety raise ethical and medical complications.
However, change is underway. Reunion Neuroscience, a New Jersey–based biotech company, is leading the first U.S. clinical trial focused on psychedelic treatment for PPD. The study involves RE104, a synthetic version of psilocybin designed to offer a shorter trip, under four hours compared to the six hours typical of classic psilocybin experiences.
The randomized, controlled trial will include 72 non-breastfeeding participants across 35 sites in the United States, with initial results expected by the second half of 2025. If successful, it could pave the way for larger trials and eventually, accessible treatments for mothers in need.
An Online Community Quietly Growing
While formal treatments are still in development, a grassroots movement has taken root online. Communities such as Moms on Mushrooms, with thousands of members, and organizations like Mothers of the Mushroom are providing a platform for mothers to exchange advice and experiences on microdosing and full-dose psilocybin journeys.
In a recent survey conducted by Mothers of the Mushroom, 411 mothers shared why they turned to psychedelics. The most common reasons included relief from depression, anxiety, and stress, as well as a desire for deeper emotional connection — both with themselves and their children. Participants frequently reported feeling more grounded, emotionally resilient, and more in sync with their families after using psilocybin.
These forums often reflect a shared sentiment: existing solutions weren’t working, and women were desperate for something, anything, that could bring them back to themselves.
Why Standard Treatments Aren’t Enough
PPD is a different beast for every sufferer. Symptoms can range from sadness and irritability to insomnia, panic attacks, and even intrusive thoughts. According to Dr. Katie Unverferth, psychiatrist and medical director of UCLA’s maternal mental health program, “It’s a very ruminative anxiety where you’re stuck in these thought loops. You feel wired, overwhelmed, and sometimes completely disconnected.”
Traditionally, treatment involves psychotherapy, SSRIs (selective serotonin reuptake inhibitors), or both. While SSRIs can be effective, they also come with side effects like emotional blunting, sexual dysfunction, nausea and weight changes. Finding the right medication and dosage often takes weeks or months — time new moms don’t feel they have.
In this instance, psilocybin once again has these traditional treatments licked; “A potential benefit of using a psychedelic for postpartum depression is to have a rapid effect,” says Dr. Leeman, a professor University of New Mexico, pointing to previous psilocybin studies that showed a positive effect on depressive symptoms within just a few days. “If we can treat the symptoms [fast] and allow the mom to bond better with her baby, there could be long-term benefits.”
In 2023, the FDA approved zuranolone, the first oral medication specifically for postpartum depression. It shows promise, with faster symptom relief than traditional antidepressants. However, it’s not widely accessible, and like SSRIs, it may not address the full emotional and relational dimensions of PPD.
Many mothers report feeling emotionally flat or disconnected while on medication, unable to access the joy, presence, or love they expect to feel with their newborns. When those conventional paths fail, some begin to wonder: Could magic mushrooms help instead?
Why Psilocybin is So Effective at Treating PPD
While modern science is still catching up, there are compelling reasons why psilocybin may be uniquely effective for treating postpartum depression.
When consumed, psilocybin is converted in the body to psilocin, which activates serotonin receptors in the brain. This alters the way different brain regions communicate, leading to a kind of mental “reboot.” According to a 2014 model developed at Imperial College London, psilocybin suppresses top-down inhibition (the brain’s internal filter system) and enhances bottom-up sensory processing, allowing for a more vivid and emotionally open experience of the world.
Another key area of interest is the default mode network (DMN) — a system of brain regions involved in self-reflection, memory, and internal thought. This network is often overactive in people with depression and is associated with rumination and negative self-talk. Psilocybin appears to temporarily disrupt the DMN, creating space for new, healthier patterns of thinking.
“It helps us understand ourselves in context,” says Dr. Ginger Nicol, a psychiatrist and professor at Washington University. The changes in brain activity triggered by psilocybin have been shown to last up to three weeks, suggesting increased neuroplasticity, the ability for the brain to form new connections and healing pathways.
Risks, Limitations, and Stigma
Despite its promise, psilocybin is not without risks. There’s little data on its presence in breast milk or its effects on infants, which is why clinical trials currently exclude breastfeeding mothers. And while psilocybin has demonstrated antidepressant effects, its impact on the anxiety component of PPD, (which is often intense and persistent) remains less studied.
Dr. Mary Kimmel, a perinatal psychiatrist at Washington University, emphasizes the need for more research. “Moms want new therapeutics,” she says. “But we need to understand how they work, who they help, and how to deliver them safely.”
Social stigma is another barrier. Many mothers who consider or use psychedelics do so in secret, fearing judgment from family, friends, and healthcare providers. Online posts often begin with disclaimers like “Please don’t judge me” or “I know this sounds crazy.”
Looking to the Future
As public awareness of psychedelic therapy grows, and trials like the one by Reunion Neuroscience move forward, the hope is that new, evidence-based treatments will emerge for mothers experiencing PPD.
For now, many moms exploring psilocybin report a common experience: a renewed sense of presence, emotional connection, and clarity. While not a cure-all, and certainly not without risks, psilocybin may represent a powerful tool in an area of mental health that’s long been underfunded and misunderstood.
With the help of psilocybin, mothers who were sinking into self-described “dark places”, found themselves able to be present with their babies again. They were able to feel the joy and love for their child that they had longed for, and step out from the shadow of anxiety that had pinned them in place. While further research is underway, it cannot be denied that magic mushrooms have transformed the lives of these mothers, and by extension, their children’s lives, for the better.
